Leon Bosquée
37 works · 691 citations · h-index 9
Top works
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
- Cervical lymphadenitis caused by a fastidious mycobacterium closely related to Mycobacterium genavense in an apparently immunocompetent woman: diagnosis by culture-free microbiological methods
- A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer
- A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer
- Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
- Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
- Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study
- Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer
- [Lung cancer. Epidemiology and etiologic factors].
- High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells.
- Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)
- Diabète insipide dans le cadre d’un carcinome pulmonaire à petites cellules : un paradoxe ?
- [Paraneoplastic endocrine syndromes: diagnosis and management].
- 95 Concomitant high-dose chemotherapy (HDCt) and radiotherapy (Rt) with G-CSF and peripheral blood stem cell (PBSC) rescue for limited (LD) small cell lung cancer (SCLC)
- Le cas clinique du mois. Cancer bronchique avance non a petites cellules avec reponse exceptionnelle aux therapies ciblees.
- Toxicite pulmonaire de la gemcitabine dans le cadre d'un CPNPC avec carcinomatose cerebrale
- Efficacy of Erlotinib in patients (PTS) with advanced non-small-cell lung cancer (NSCLC) relative to clinical charesteristics : subset analyses from the trust study
- Le cancer du poumon. Epidemiologie et facteurs etiologiques.
- P-587 Experience from a large multi-centre expanded access programme (EAP) with gefitinib (‘Iressa’, ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC)
- LE DÉFI DU CONTRÔLE LOCAL DANS LE CANCER PULMONAIRE NON A PETITES CELLULES, LOCALEMENT AVANCE, NON OPERABLE